Kinzbio’s mission is to harness the power of phages—nature’s precision antimicrobials—to address some of the world’s most challenging infections. As a pioneering clinical and commercial-stage biotech company based in Uruguay, we are thrilled to share a series of milestones that highlight our progress, and lay the groundwork for future growth and collaborations.Personalized Phage Treatments in Uruguay: a ground-breaking achievement

Kinzbio successfully delivered Uruguay’s first-ever personalized phage treatments, achieving microbial eradication in cases of complicated lung infections and prosthetic joint infections. This milestone not only demonstrates the transformative potential of phage therapy but also marks a major step forward in bringing personalized medicine to the forefront in Latin America. The outcomes of these treatments were recently presented at the National Clinical Pathology Conference in Uruguay. Kinzbio’s precision phage-based antibiotics are already available to critical and chronic patients in Uruguay, where the Ministry of Health has provided regulatory clearance to Kinzbio for commercialization.

Media Coverage

Our work caught the attention of BBC News, further validating the global relevance of our mission. You can read it here (in Spanish).

Strategic Leadership Expansion

Kinzbio proudly welcomed Patrick Guye as the first Independent Non-Executive Director on our Board. Patrick brings a wealth of experience in biotechnology and life sciences, positioning Kinzbio for strategic growth.

Entry into the Eretz.Bio Acceleration Program

We were selected for the prestigious Eretz.Bio Acceleration Program at Albert Einstein Hospital in São Paulo, Brazil. This program will help us prepare for expansion into Brazil’s healthcare ecosystem.

Leadership in the Phage Community

As the main sponsor of the upcoming Phage Option conference in Cartagena, Colombia (December 4–6), we are taking a leading role in fostering collaboration within the phage community across Latin America. Additionally, on November 19, we will attend the Phage Futures conference in Boston, a key event to connect with global leaders in phage therapy.

Secured Non-Dilutive Funding

Our innovation and impact were recognized by Uruguayan agencies, ANII (Agencia Nacional de Investigación e Innovación) and the Ministry of Industry, Energy, and Mining (MIEM), through the award of ~$150k USD in non-dilutive funding. These resources will accelerate the development of our pipeline and infrastructure.

Recognition at OktoberINVESTFest Latam

Kinzbio was one of the 10 startups selected to pitch at the OktoberINVESTFest Latam in Lima, Peru. This premier networking and fundraising event, organized by the State of Bavaria Office for South America, brought together key venture capital players from Latin America and Germany, opening new opportunities for investment and collaboration.

A post by Kinzbio

Just like Kinzbio, INCATE encourages all our ventures to share their exciting opportunities, connections, and milestones. We’d love to hear from you!

Reach out to us at comms@incate.net and let us know what you’ve been up to.